465 related articles for article (PubMed ID: 16355501)
1. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
[TBL] [Abstract][Full Text] [Related]
2. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
3. Clinical performance of six different serum tartrate-resistant acid phosphatase assays for monitoring alendronate treatment.
Fagerlund KM; Janckila AJ; Ylipahkala H; Tiitinen SL; Nenonen A; Cheng S; Uusi-Rasi K; Yam LT; Väänänen HK; Halleen JM
Clin Lab; 2008; 54(9-10):347-54. PubMed ID: 19097492
[TBL] [Abstract][Full Text] [Related]
4. Age-related changes of serum tartrate-resistant acid phosphatase 5b and the relationship with bone mineral density in Chinese women.
Qin YJ; Zhang ZL; Zhang H; Hu WW; Liu YJ; Hu YQ; Li M; Gu JM; He JW
Acta Pharmacol Sin; 2008 Dec; 29(12):1493-8. PubMed ID: 19026169
[TBL] [Abstract][Full Text] [Related]
5. Biochemical markers of bone metabolism and prediction of fracture in elderly women.
Gerdhem P; Ivaska KK; Alatalo SL; Halleen JM; Hellman J; Isaksson A; Pettersson K; Väänänen HK; Akesson K; Obrant KJ
J Bone Miner Res; 2004 Mar; 19(3):386-93. PubMed ID: 15040826
[TBL] [Abstract][Full Text] [Related]
6. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
7. Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model.
Rissanen JP; Suominen MI; Peng Z; Halleen JM
Calcif Tissue Int; 2008 Feb; 82(2):108-15. PubMed ID: 18084692
[TBL] [Abstract][Full Text] [Related]
8. Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption.
Hannon RA; Clowes JA; Eagleton AC; Al Hadari A; Eastell R; Blumsohn A
Bone; 2004 Jan; 34(1):187-94. PubMed ID: 14751577
[TBL] [Abstract][Full Text] [Related]
9. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
[TBL] [Abstract][Full Text] [Related]
10. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
11. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction.
Yamada S; Inaba M; Kurajoh M; Shidara K; Imanishi Y; Ishimura E; Nishizawa Y
Clin Endocrinol (Oxf); 2008 Aug; 69(2):189-96. PubMed ID: 18221403
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
13. Serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density.
Halleen JM; Ylipahkala H; Alatalo SL; Janckila AJ; Heikkinen JE; Suominen H; Cheng S; Väänänen HK
Calcif Tissue Int; 2002 Jul; 71(1):20-5. PubMed ID: 12073156
[TBL] [Abstract][Full Text] [Related]
14. TRACP 5b and CTX as osteological markers of delayed fracture healing.
Moghaddam A; Müller U; Roth HJ; Wentzensen A; Grützner PA; Zimmermann G
Injury; 2011 Aug; 42(8):758-64. PubMed ID: 21168135
[TBL] [Abstract][Full Text] [Related]
15. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
[TBL] [Abstract][Full Text] [Related]
16. The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
Gossiel F; Ugur A; Peel NFA; Walsh JS; Eastell R
Osteoporos Int; 2022 Jun; 33(6):1357-1363. PubMed ID: 35102444
[TBL] [Abstract][Full Text] [Related]
17. The clinical utility of serum tartrate-resistant acid phosphatase 5b in the assessment of bone resorption in patients on peritoneal dialysis.
Yamada S; Tsuruya K; Yoshida H; Taniguchi M; Haruyama N; Tanaka S; Eriguchi M; Nakano T; Kitazono T
Clin Endocrinol (Oxf); 2013 Jun; 78(6):844-51. PubMed ID: 23078546
[TBL] [Abstract][Full Text] [Related]
18. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Sarioglu M; Tuzun C; Unlu Z; Tikiz C; Taneli F; Uyanik BS
Rheumatol Int; 2006 Jan; 26(3):195-200. PubMed ID: 15580349
[TBL] [Abstract][Full Text] [Related]
20. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]